AtriCure (NASDAQ:ATRC) Releases FY 2026 Earnings Guidance

AtriCure (NASDAQ:ATRC) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 0.240-0.320 for the period, compared to the consensus estimate of 0.120. The company issued revenue guidance of $602.0 million-$610.0 million, compared to the consensus revenue estimate of $605.0 million.

Analyst Ratings Changes

ATRC has been the subject of a number of analyst reports. Zacks Research downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 4th. Freedom Capital upgraded AtriCure to a “strong-buy” rating in a research note on Wednesday, April 1st. Raymond James Financial set a $52.00 price objective on AtriCure in a research report on Tuesday. Weiss Ratings cut AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 4th. Finally, Citigroup reissued a “market outperform” rating on shares of AtriCure in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, AtriCure currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.12.

AtriCure Stock Down 1.6%

AtriCure stock traded down $0.54 during trading hours on Thursday, hitting $32.98. The stock had a trading volume of 1,136,409 shares, compared to its average volume of 784,314. The stock’s 50-day moving average price is $29.81 and its 200-day moving average price is $31.44. The stock has a market capitalization of $1.67 billion, a P/E ratio of -329.80 and a beta of 1.24. AtriCure has a 12-month low of $25.36 and a 12-month high of $43.18. The company has a quick ratio of 3.18, a current ratio of 4.29 and a debt-to-equity ratio of 0.15.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The firm had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a negative net margin of 0.83% and a positive return on equity of 0.29%. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities research analysts anticipate that AtriCure will post 0.13 EPS for the current fiscal year.

Insider Activity at AtriCure

In other AtriCure news, Director Karen Prange sold 3,000 shares of AtriCure stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $28.65, for a total value of $85,950.00. Following the completion of the sale, the director owned 26,373 shares of the company’s stock, valued at approximately $755,586.45. This trade represents a 10.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.00% of the company’s stock.

Institutional Investors Weigh In On AtriCure

Large investors have recently bought and sold shares of the business. Marshall Wace LLP boosted its holdings in AtriCure by 63.4% in the 4th quarter. Marshall Wace LLP now owns 913,453 shares of the medical device company’s stock worth $36,136,000 after buying an additional 354,281 shares during the period. Wellington Management Group LLP raised its holdings in AtriCure by 8.1% during the third quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock valued at $151,296,000 after acquiring an additional 322,818 shares during the period. First Light Asset Management LLC raised its holdings in AtriCure by 32.0% during the fourth quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company’s stock valued at $46,501,000 after acquiring an additional 285,083 shares during the period. Norges Bank purchased a new position in shares of AtriCure in the fourth quarter valued at about $8,466,000. Finally, Oberweis Asset Management Inc. purchased a new position in shares of AtriCure in the third quarter valued at about $5,411,000. 99.11% of the stock is currently owned by institutional investors.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.